Contradictory to studies showing that AKT inhibitors can target multiple RTKs in various cancer cell types, the PI3K/mTOR inhibitor BEZ235 did not significantly alter the activity of different STAT3-regulating RTKs in PTEN-deficient gastric cancer cells. The gene discussed is AKT1; the disease is gastric cancer.